# Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)

> **NCT02108860** · PHASE3 · COMPLETED · sponsor: **University of South Florida** · enrollment: 65 (actual)

## Conditions studied

- Granulomatosis With Polyangiitis (Wegener's)
- Granulomatosis With Polyangiitis
- Wegener's Granulomatosis
- ANCA-Associated Vasculitis

## Interventions

- **DRUG:** Abatacept
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02108860
- **Lead sponsor:** University of South Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-25
- **Primary completion:** 2023-07-25
- **Final completion:** 2023-12-20
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2024-07-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02108860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02108860, "Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02108860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*